ARYx Therapeutics, Inc. (ARYX)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Aug 11, 2025
ARYx Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | 2004 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '10 Sep 30, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | Dec '07 Dec 31, 2007 | Dec '06 Dec 31, 2006 | Dec '05 Dec 31, 2005 | 2004 |
| Revenue | - | - | 19.72 | 4.16 | 4.74 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | 374.36% | -12.26% | - | - | Upgrade
|
| Cost of Revenue | - | - | 0.23 | 0.26 | 2.12 | - | Upgrade
|
| Gross Profit | - | - | 19.49 | 3.9 | 2.62 | - | Upgrade
|
| Selling, General & Admin | 8.07 | 10.2 | 10.07 | 7.7 | 6.94 | 5.67 | Upgrade
|
| Research & Development | 7.06 | 21.04 | 39.84 | 24.99 | 23.97 | 22.5 | Upgrade
|
| Operating Expenses | 15.13 | 31.24 | 49.91 | 32.7 | 30.91 | 28.17 | Upgrade
|
| Operating Income | -15.13 | -31.24 | -30.42 | -28.8 | -28.29 | -28.17 | Upgrade
|
| Interest Expense | -1.69 | -2.01 | -1.93 | -1.35 | -1.32 | -0.67 | Upgrade
|
| Interest & Investment Income | 0.07 | 0.09 | 1.26 | 2.59 | 2.29 | 0.88 | Upgrade
|
| EBT Excluding Unusual Items | -16.75 | -33.15 | -31.09 | -27.56 | -27.32 | -27.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.02 | -0.01 | -0.13 | - | - | - | Upgrade
|
| Pretax Income | -18.33 | -33.17 | -31.22 | -27.56 | -27.32 | -27.96 | Upgrade
|
| Earnings From Continuing Operations | -18.33 | -33.17 | -31.22 | -27.56 | -27.32 | -27.96 | Upgrade
|
| Net Income | -18.33 | -33.17 | -31.22 | -27.56 | -27.33 | -27.96 | Upgrade
|
| Net Income to Common | -18.33 | -33.17 | -31.22 | -27.56 | -27.33 | -27.96 | Upgrade
|
| Shares Outstanding (Basic) | 31 | 27 | 19 | 3 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 27 | 19 | 3 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 17.87% | 44.69% | 466.77% | 228.68% | 11.87% | 6.06% | Upgrade
|
| EPS (Basic) | -0.59 | -1.21 | -1.65 | -8.24 | -26.84 | -30.73 | Upgrade
|
| EPS (Diluted) | -0.59 | -1.21 | -1.65 | -8.24 | -26.84 | -30.73 | Upgrade
|
| Free Cash Flow | -20.12 | -35.11 | -45.86 | -28.2 | -5.18 | -26.28 | Upgrade
|
| Free Cash Flow Per Share | -0.65 | -1.28 | -2.42 | -8.43 | -5.08 | -28.88 | Upgrade
|
| Gross Margin | - | - | 98.82% | 93.70% | 55.35% | - | Upgrade
|
| Operating Margin | - | - | -154.21% | -692.64% | -596.92% | - | Upgrade
|
| Profit Margin | - | - | -158.27% | -662.84% | -576.66% | - | Upgrade
|
| Free Cash Flow Margin | - | - | -232.52% | -678.31% | -109.20% | - | Upgrade
|
| EBITDA | -14.18 | -30.16 | -29.32 | -27.79 | -27.46 | -27.61 | Upgrade
|
| EBITDA Margin | - | - | -148.65% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.95 | 1.08 | 1.1 | 1.01 | 0.83 | 0.56 | Upgrade
|
| EBIT | -15.13 | -31.24 | -30.42 | -28.8 | -28.29 | -28.17 | Upgrade
|
| EBIT Margin | - | - | -154.21% | - | - | - | Upgrade
|
| Revenue as Reported | - | - | 19.72 | 4.16 | 4.74 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.